Semtech Analyst Day Review
Semtech raised Q3 guidance and targets $3.2 billion of fiscal 2030 revenue, excluding upside from its AI data-center optical and copper interconnect businesses.
Semtech raised Q3 guidance and targets $3.2 billion of fiscal 2030 revenue, excluding upside from its AI data-center optical and copper interconnect businesses.
@Aureliusltd28 I like $FCNCA from this list.
Andrew hosted me on his podcast. We talked about $NYCB, $COF, $DFS, $HOOD, and $FCNCA. https://t.co/CjxnHfVPI2
New Idea Brunch interview with @WhiteFalconCap is out Balkar goes over his past picks, including $NU which is up ~150%, and shares some of his new top ideas! https://t.co/iLoVkWVHIc
$CART Moved forward its lock-up expiration date to 2/16 (Thursday) from the original 3/19. >65% of the shares will be eligible for sale. COO leaving, just announced a restructuring w ambitious guidance. Almost certainly did so to support the stock in advance of a secondary.
$YOU Delta just significantly expanded its Digital ID program. This service is free, more efficient than Clear and now available in Clear's core markets. Other majors will have to follow in order to compete on service. Seems like this could kill $YOU in pretty short order. https://t.co/tgfebZZCWK
$YOU sales growth in light blue, Members in orange vs QTD web traffic. Dotted section is Q4 w consensus sales and member growth. https://t.co/NcihE7pbyD
$YOU Clear supervisor at JFK said they’ve experienced “a surge in new sign-ups from pre-Thanksgiving through the Christmas travel period.” Similarweb web traffic to their site shows a large acceleration in visits as well suggesting a potentially large Q4 earnings beat.
Brian Bellinger is one of the best small-cap investors you've never heard of. His Idea Brunch pick from 2021 has more than tripled and his new interview is one of our favorites Read the full interview with Idea Pitches below $JAKK $INSP https://t.co/HKpmjqWyic
Steve Eisman examines AI data-center debt, CoreWeave's tech correction and agentic AI's effect on banks as earnings season begins.
CoreWeave’s debt and equity price action is framed as a wake-up call for investors amid a broader market discussion.
PesoRama will reach 54 JOi Dollar Plus stores by November after raising C$28.4 million, funding more than 50 additional Mexican store…
Modine, soon Modexus Solutions, has a $4 billion hyperscaler cooling contract but must ramp factory output and restore margins as data…
AppLovin rebuilt its ad model with AXON 2.0, lifting LTM revenue to about $7 billion and margins to 77% as Unity competition threatens…
Brookfield Asset Management's fee revenue rose 16.2% and distributable earnings 15.8%, but its 18% five-year target relies on AI-led growth…
Marvell is positioning networking, optical connectivity and server-management chips as AI data centers link GPUs, custom accelerators and…
AeroVironment's $465M LOCUST laser award and earnings beat support its 2027 growth outlook despite government budget uncertainty.
Constellation Brands trades near $127 at roughly 11x next-twelve-month EV/EBIT, with recent business results offsetting concerns over…
Transocean’s Valaris merger clears regulators, creating a 68-rig offshore driller controlling four in 10 global drillships.
SPHR · long Sphere Entertainment is shifting from construction and startup spending to a high-margin, cash-generative venue-operator model, with…
October 2026 market commentary covers SOLS’s cancelled merger, a hypothetical Starbucks-Chipotle deal, Russell 2000 weakness and AI…
CoreWeave faces fresh skepticism as another AI trade selloff collides with bullish defenses of the company.
Ari Emanuel discusses AI’s impact on Hollywood, live events, social networks and the future of advertising.
RTX’s $289 billion backlog, including $119 billion in defense, supports growth from defense contracts and commercial aerospace aftermarket…
Peabody Energy’s recovery case hinges on Centurion, coal-market leverage, capital allocation and balance-sheet strength amid commodity…
Applied Materials leads wafer-fab deposition and ranks third in etch, positioning it for tougher 3D chip manufacturing as investors weigh a…
First Tracks Biotherapeutics’ ANB033 posted stronger Phase 1b celiac efficacy than Teva’s IL-15 inhibitor, with $168 million funding…
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.